Avenue Therapeutics’ (NASDAQ:ATXI) BAER-101, its potentially best-in-class selective GABA-A alpha2,3 positive allosteric modulator significantly suppressed seizures in a translational animal model of absence epilepsy.
“These preclinical results demonstrate the potential of BAER-101 to improve the current treatment landscape of epilepsy with a differentiated approach designed to improve the safety profile, compared with existing drugs, which are often not well-tolerated due to side effects, including sedation, cognitive impairment, ataxia and addiction,” Alexandra MacLean, M.D. and CEO of Avenue, said in a statement.
“As we advance toward potentially initiating a Phase 2a study in 2024, we are encouraged by these results, showing BAER-101’s best-in-class potential for patients with increased tolerability, potency and efficacy,” she added.
Amy Chappell, M.D., said BAER-101 creates an “opportunity to improve the treatment of seizures in a field where many of the approved treatments have limited efficacy and/or are dose-limited by side effects.”
